Abstract Neutrophils and mononuclear cells are implicated in the pathogenesis of several inflammatory conditions including chronic obstructive pulmonary disease (COPD). Neutrophil-derived serine proteases, such as cathepsin G (CG) and neutrophil elastase (NE), may interact with mononuclear cells via protease-activated receptors (PARs), which are seven-transmembrane G protein-coupled receptors activated by proteolytic cleavage of the extracellular N-terminus, and which, on activation, induce the release of several mediators and cytokines.We determined whether CG and NE could affect PAR-1 expression and function in mononuclear cells. Human blood mononuclear cells were isolated from 20 healthy donors.Surface andintracellular receptor expression and calcium mobilisation (using the calcium chelator,FLUO3-AM) were studied by fluorescence-assisted cell sorting (FACS analysis). Positive controls, i.e. thrombin (0.1^100 mU/ml) and the PAR-1-activating peptide SFLLRN (100 mM), induced a rapid and transient internalisation of PAR-1 in monocytes and lymphocytes. CG but not NE had a similar effect. By contrast, in monocytes intracellular calcium mobilisation was induced by thrombin and SFLLRN but not by CG and NE.Thus,CG can induce intracellular PAR-1 sequestration without activation of the receptor, and may act as an antagonist and prevent subsequent activation of PAR-1in mononuclear cells. These findings may be of relevance to the pathogenesis of COPD. r
INTRODUCTION
Protease-activated receptors (PARs, PAR-1 to PAR-4) are seven-transmembrane G protein-coupled receptors that are activated through unique mechanism of sitespeci¢c cleavage by serine proteases (1) .The main agonist of PAR-1, PAR-3 and PAR-4 is thrombin, while trypsin is the most potent agonist of PAR-2 (1^3). Several PARmediated e¡ects may be relevant in airway diseases: PAR-1 and PAR-2 have been shown to regulate bronchoconstrictor responses of human airways and release of several cytokines and mediators by monocytes/macrophages, mast cells, endothelial and epithelial cells, ¢bro-blasts and smooth muscle cells (4^10).
The site of cleavage of PARs by serine-proteases is located on the NH 2 -terminal exodomain of the receptor; cleavage yields a new NH 2 terminus, which acts as a tethered ligand and binds to, and activates the receptor (1) . Activation of these receptors is an irreversible phenomenon; cleaved receptors are phosphorylated, uncoupled from their G protein, internalised and degraded in lysosomes, while cell sensitivity to their agonists is restored by new receptors which arise from an intracellular pool (11) . Some proteases can cleave PARs at sites located downstream of the tethered ligand, or cleave the tethered ligand itself, thereby rendering the receptor inactive and/or unresponsive to subsequent enzymatic activation (1) . Neutrophil elastase (NE) is one of the enzymes that may inhibit activation of PAR-1 by this mechanism, while cathepsin G (CG), another neutrophil serine protease, can both activate PAR-1 by cleavage at the thrombin site and inactivate it by downstream cleavage (1) .
PARs are widely distributed and are expressed in several cell types (1) including monocyte/macrophages and lymphocytes. Therefore, we hypothesised whether these cells could be a¡ected by neutrophil serine proteases through PAR-1cleavage. Such an interaction could occur in chronic in£ammatory conditions such as chronic obstructive airways disease in which there is accumulation of monocytes/macrophages,T lymphocytes and neutrophils, and in which products of activated neutrophils such as NE and CG may play a major role (12, 13) . We determined the e¡ects of NE and CG on the expression and function of PAR-1in monocytes and lymphocytes, by using £uorescence-assisted cell sorting (FACS) to examine the internalisation and recycling of receptors and their coupling to intracellular calcium release.
MATERIAL AND METHODS

Isolation of peripheral blood monocytes
Peripheral venous blood from 20 healthy non-smoking volunteers was mixed with acid-citrate dextrose (1:6 vol/vol) and sedimented on dextran (6% in 0.9% NaCl) for 40 min. Mononuclear cells were separated by Ficoll-Hypaque density centrifugation. Cells were washed twice with Hanks' balanced salt solution (HBSS) and plated at a concentration of1 Â10 6 monocytes/1ml in 12-well plates.Cell viability was consistently 496% as assessed by trypan blue exclusion. At 24 h, cells were used to study the e¡ect of agonists on calcium £ux and PAR-1 surface expression.
Regulation of PAR-1 expression
PAR-1 expression was assessed by FACS. Two preliminary experiments were performed to determine the time-course of PAR-1 expression: ¢rstly, we assessed the kinetics of the decrease in PAR-1expression after incubation with SFLLRN (PAR-1agonist,100 mM) for10, 30, 60, 120, and 240 min (n = 3 for each condition). Secondly, we studied the kinetics of PAR-1 re-appearance: cells were ¢rst incubated with SFLLRN during1h before being washed and incubated in SFLLRN-free medium for 0, 2, 4 or 24 h (n = 3 for each condition).
To study the e¡ects of agonists and enzymes, cells were incubated for 1 h in the presence of medium alone or containing the tested agent.Optimal dosage of tested agents was ¢rst assessed by dose^response experiments with concentrations of 1, 10 and 100 mM for SFLLRN; 1, 10 and 100 U/ml for thrombin; 10
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, 10 À8 and 10 À7 M for CG; 10
À8
,10
À7
, and10 À6 M for NE; and1,10 and 100 mM for PAR-1antagonist peptide (H^Met^Ser^ArgP ro^Ala^Cys^Pro^Asn^Asp^Lys^Tyr^Glu^OH, negative control) (N = 3 per condition). The e¡ect of the optimal dosage of each agent was then con¢rmed in three additional samples.
After incubation, cells were harvested by scraping, washed in 1ml HBSS, and re-suspended in 100 ml Dubelcco's PBS without calcium and magnesium. In order to assess surface expression of PAR-1, cells were incubated during 30 min with anti-PAR-1phycoerythrin (PE)-conjugated antibody (7:100 vol/vol).Two antibodies were used: SPAN12, which identi¢es intact receptors only, and WEDE15, which identi¢es both intact and cleaved receptors. To identify monocytes, cells were also simultaneously incubated with £uorescein isothyocyanate (FITC)-conjugated mouse monoclonal anti-CD14 monoclonal antibodies (7:100). To assess the intracellular pool of PAR-1, cells were ¢rst incubated with anti-CD14 antibody before being permeabilised using DAKO IntraStain Kit (Cambridge, U.K.), and incubated with anti-PAR-1 SPAN12 or WEDE15 antibodies. After a ¢nal wash, cells were re-suspended in £ow cytometry bu¡er (FACSFlow, Becton Dickinson, San Jose, CA, U.S.A.) containing 1% paraformaldehyde, and £uorescence was measured by a FACScan £ow cytometer (Becton Dickinson, San Francisco,CA,U.S.A.).Forward scatter (FSC) and side scatter (SSC) characteristics were recorded on a linear scale while £uorescence at 530 nm (FL1 channel) and 670 nm (FL2 channel) were recorded on a logarithmic scale. Lymphocytes and monocytes were identi¢ed using both the FSC^SSC and intensity of CD14 staining as recorded on the FL1channel, in which emissions from FITC conjugates are recorded. To assess PAR-1 expression, we analysed the percentage of gated cells and the mean (MFI) and speci¢c (SFI) £uorescence intensity of each cell type in the FL2 histograms, since PE-conjugates emit in the FL2 channel. A PE-conjugated mouse IgG2a with no known reactivity to human antigens was used as isotype control. Speci¢c £uorescence intensity was calculated as follows: SFI = sample MFI^isotype control MFI.
Measurement of intracellular calcium mobilisation
Measurement of intracellular calcium mobilisation was performed using £ow cytometry with Fluo3/AM, a £uor-escent calcium chelator which enters cells where it is metabolised to membrane-impermeant Fluo3.The spontaneous £uorescence of Fluo3 increases after calcium chelation and can be read at 530 nm (FL1 channel) after excitation at 488 nm. Cells were ¢rst incubated during 15 min in RPMI medium containing 2 mM of Fluo3/AM, harvested by scraping and washed twice in HBSS before being resuspended in 0.5 ml of phenol red-free RPMI1640 in 5-ml rounded-bottom polypropylene tubes (Falcon). Thirty minutes later, measurements were performed using a FACScan £ow cytometer (Becton Dickinson); after two reproducible (o5% variation) baseline measurements, tested agents were added at the optimal concentration that induced a decrease in receptor expression (SFLLRN, 100 mM; thrombin, 100 U/ml; cathepsin G,10 À8 M; neutrophil elastase,10 À6 M; and PAR-1 antagonist peptide, 100 mM). Then, £uorescence in the FL1 channel was recorded repeatedly until baseline values were reached again. When no response was observed, recordings were repeated during 1h. At least 5000 events were recorded for each measurement and four experiments were performed for each tested agent. For the analysis, a FSC^SSC dot plot was used to gate on monocytes and lymphocytes, and changes of mean FL1 £uorescence intensity (MFI) in each gate were analysed.
Reagents
Complete monocyte/macrophage culture medium was RPMI-1640 (ICN-Flow, High Wycombe, U.K.) containing 10% heat-inactivated fetal calf serum (Sera Lab, Crawley, U.K.), 2 mM L-glutamine (ICN-£ow), and penicillin-streptomycin (100 U/ml^100 ml, ICN £ow). Culture plates were from Falcon (London, U.K.). PAR-1 agonist peptide SFLLRN (PAR-1) was from Bachem (Sa¡ron Walden, U.K.). Thrombin (1000 NIH Units/ml) was from Sigma, elastase (150 U/mg of protein) was from Calbiochem (Nottingham, U.K.), and cathepsin G (2^4 U/mg) was from ICN-Flow. Anti-PAR-1 antibodies were from Santa Cruz Biotechnology (Calne, U.K.). FITC-conjugated monoclonal anti-CD14 mouse IgG2a was from Sigma. Fluo3/AM was from Alexis corporation (Nottingham, U.K.).
Data analysis
Results are expressed as mean7SEM. Comparisons were performed using non-parametric tests. A threshold of P40.05 was considered for statistical signi¢cance. All statistics were performed using SPSS 7.5 software (SPSS Inc., Chicago, IL, U.S.A).
RESULTS
Regulation of PAR-1 expression
PAR-1 was expressed by 44% of lymphocytes and 28% of monocytes at baseline (P40.01) but SFI was similar in the two cell types. The decrease in PAR-1 expression after exposure to SFLLRN (100 mM) was maximal at 10 min in lymphocytes and at 60 min in monocytes (Fig 1) . Therefore, subsequent experiments were studied after 1h incubation. PAR-1 surface expression returned to baseline levels 2 h after cessation of exposure in both monocytes and lymphocytes (Fig.1) .
The surface expression of intact and total (intact+-cleaved) PAR-1 in lymphocytes and monocytes was markedly decreased after incubation in the presence of SFLLRN (concentration for maximal e¡ect: 100 mM), thrombin (concentration for maximal e¡ect: 100 U/ml), CG (concentration for maximal e¡ect: 10 À8 M) while elastase (concentration up to 10 À6 M) and PAR-1 antagonist peptide (100 mM) had no signi¢cant e¡ect (Fig 2) . In parallel, the intracellular expression of intact and total PAR-1 was not a¡ected by SFLLRN, thrombin and CG (data not shown).
Intracellular calcium mobilisation
In monocytes, SFLLRN and thrombin but not CG and NE elicited a transient intracellular calcium £ux (Fig 3) . We could not obtain reproducible results in lymphocytes, which is likely due to an insu⁄cient sensitivity of the FACS method for assessing calcium mobilisation in these cells.
DISCUSSION
We have shown that both monocytes and lymphocytes express PAR-1, and that this expression is markedly reduced by exposure to known PAR-1 agonists such as thrombin and the peptide SFLLRN. Of the two neutrophil serine proteases, CG but not elastase also caused a reduction in PAR-1receptor expression in both lymphocytes and monocytes. Reduction of PAR-1 expression after exposure to SFLLRN was maximal at 1h; expression recovered 2 h after washing-o¡ of the peptide but remained low in case of prolonged exposure.The calcium release data indicate that both cathepsin and elastase do not induce intracellular calcium release, despite the ability of CG to induce internalisation of PAR-1 receptors. However, thrombin and the PAR-1 agonist, SFLLRN, both induce calcium mobilisation, thrombin being a more potent e¡ector in this respect. Altogether, these data indicate that CG could act as an antagonist at the PAR-1 receptor.
Peripheral blood lymphocytes and monocytes have both been shown to express PAR-1 mRNA (14, 15) . Although the functional signi¢cance of PAR-1 activation in these cells is not known, this receptor seems to participate in in£ammatory phenomena: in monocytes, the activation of PARs induces the release of several chemotactic or pro-in£ammatory cytokines including monocyte chemotactic protein-1, IL-1b, TNF-a and IL-6 [1,151 8] . Since lymphocytes, monocytes and neutrophils are the main in£ammatory cells involved in the pathogenesis of airway in£ammation and damage in chronic obstructive pulmonary disease (COPD) (12,13), our hypothesis was that neutrophil serine proteases could modulate mononuclear cells activation through e¡ects on PAR-1. Studies with PAR-1antagonists and cross-desensitisation experiments remain to be perfomed to test this possibility. Protease inhibitors would not be suitable in this respect since they do not avoid non-speci¢c enzymatic e¡ects mediated by pathways other than PAR-1.
NE and CG are both products of activated neutrophils, which are recruited to and activated in the airways of COPD patients (12, 19) , and produce increased amounts of NE; this enzyme is involved in the development of emphysema through its e¡ect on the extracellular matrix (20, 21) and induces goblet cell degranulation (22, 23) , plasma protein extravasation (24) , epithelial cell detachment, and production of IL-8 and PGE 2 by epithelial cells (21) . CG also causes mucus secretion and epithelial cell detachment (21, 25) and induces airway hyperresponsiveness (26) .Our data indicate that neutrophil serine proteases are not signi¢cant activators of intracellular calcium mobilisation in monocytes despite the clear expression of functional PAR-1 by these cells and the potential ability of CG to cleave this receptor at the thrombin activating site.Conversely, CG appears capable of causing intracellular sequestration of PAR-1 receptors in both monocytes and lymphocytes without receptor activation, which illustrates the dissociation between these two events. This may lead to cellular desensitisation, thereby preventing further PAR-1 activation by thrombin or CG itself.
One potential limitation of our study of PAR-1 internalisation is that, in preliminary studies, we assessed the kinetics of this phenomenon only with PAR-1 agonist peptide SFLLRN; but this may di¡er with CG, elastase or thrombin. However, these agonists act much more quickly than the agonist peptides, which are are also less potent. The reason for this is that the 3D conformation of the uncleaved receptor, in which the unaltered NH 2 terminus partially masks the ligand binding site, makes it less accessible. In addition, in both monocytes and lymphocytes, a signi¢cant e¡ect was observed between 10 min and 4 h after SFLLRN addition, making it unlikely to miss an e¡ect of enzymatic agonists at 1h. Finally, the lack of intracellular calcium mobilisation that we observed after stimulation with CG is unlikely to be related to a di¡erence in kinetics since all samples were studied up to 1h after addition of studied agents, the e¡ect of SFLLRN and thrombin being observed within 5 min.
PAR-1 is present on both the plasma membrane and intracellularly. There is a substantial intracellular pool, from which new receptors are translocated to the plasma membrane to restore cell sensitivity to PAR-1 agonists (1) . Activated cell surface PAR-1 is known to be rapidly internalised and then sorted out predominantly to lysosomes (27) .This is in agreement with the decrease in PAR-1surface expression, but not in global cellular expression that we found after exposure to thrombin and the peptide SFLLRN, which both induced cell activation as assessed by intracellular calcium mobilisation. Receptor internalisation, which is mediated by phosphorylation of the cytoplasmic tail of the receptor, has also been found to occur independently of activation, either spontaneously (as part of a permanent tra⁄cking between plasma membrane and intracellular pool) or after nonactivating cleavage (11,27^31) . Such a phenomenon is consistent with our ¢ndings with CG, which induced a decrease in surface PAR-1 expression in the absence of calcium signal. CG can cleave PAR-1 at the thrombin site Arg 41 kSer 42 but also at two non-activating sites located downstream to the thrombin site, i.e., Phe 43 kLeu 44 and Phe 55 kTryp 56 [32] . This non-activating cleavage leads to removal of the tethered ligand and generates an unresponsive receptor that is internalised and degraded (27) . Thus, our ¢ndings with CG may re£ect a predominance of non-activating over activating cleavage of PAR-1 in human monocytes, subsequently rendering the cell unresponsive to activation by CG or thrombin. This is in agreement with the data of Molino et al. in platelets and endothelial cells, in which activating cleavage was prevented by removal of the tethered ligand through downstream cleavage by CG at the Phe 55 kTryp 56 site (32). We did not ¢nd any evidence of PAR-1 internalisation after exposure to elastase, which also did not induce any detectable calcium mobilisation. However, a non-activating PAR-1 cleavage site by elastase has been identi¢ed (33) . Our ¢ndings suggest that such a cleavage either does not occur (e.g. because the cleavage site is not su⁄-ciently accessible due to molecular conformation of surface PAR-1), or does not induce the signalling which is required to produce receptor internalisation (i.e. phosphorylation of intracellular carboxy-terminal tail).
In conclusion, our data indicate that the neutrophil enzymes, CG and NE, do not activate mononuclear in£am-matory cells through PAR-1 cleavage.
